Skip to main content
Premium Trial:

Request an Annual Quote

Microcide Agrees to Acquire Althexis; Joint Company Receives $60M in Financing

NEW YORK, July 30 – Microbial genomics company Microcide Pharmaceuticals said Monday it had signed an agreement to acquire Althexis in an effort to step-up its drug discovery capabilities.

Microcide of Mountain View, Calif., and Althexis of Waltham, Mass., also announced that the combined company would receive $60 million in a private round of financing. Prospect Venture Partners, New Enterprise Associates, and Schroder Ventures are particpating in the placement.

Microcide has developed VALID, a system for studying microbial genomics, while Althexis uses structure-based methods, known as ACTT, to validate drug targets.

"The integration of Althexis' proprietary ACTT technology with Microcide's VALID platform will help speed target validation and new compound discovery, while Althexis' SBDD will help guide our multiple lead-optimization efforts to achieve better drug candidates, sooner," Jim Rurka, CEO of Microcide, said in a statement.

Mark Skaletsky, formerly chairman and CEO of Althexis, will become chairman and CEO of Microcide. Rurka will remain a member of Microcide’s board of directors. 

Under the terms of the agreement, Microcide will issue about 5.3 million shares of its common stock for all of the outstanding shares of Althexis. The deal is valued at approximately $22.2 million, based on Microcide’s Friday closing price of $4.19.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.